Project Grant R01AI181261
Award Date
5/2/25
Completion Date
4/30/29
Dollars Obligated
$599K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $682,879 to The Medical College of Wisconsin, Inc. to conduct research on the impact of human cytomegalovirus (HCMV) infection on developing human neural tissues and brain function. The research aims to: 1) define the transcriptional and cellular disruptions to developing human neural cells caused by HCMV...
The University of California, Davis was awarded a $232,415 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this 2-year project is to prevent primary cytomegalovirus (CMV) infection through prophylactic passive vaccination with a highly potent CMV IL-10 neutralizing monoclonal antibody. The researchers aim to 1) characterize and purify highly potent viral IL-10 neutralizing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $775,986 to support research focused on mitigating cytomegalovirus (CMV) reactivation in kidney transplant recipients. The research aims to identify cellular and molecular targets for developing tissue-specific strategies to prevent CMV reactivation and improve transplant outcomes. Specifically, the project...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,995 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Icahn School of Medicine at Mount Sinai to develop novel inhibitors targeting human cytomegalovirus (CMV) infection. The grant aims to characterize the mechanism of action and optimize a series of N-arylpyrimidinamine (NAPA) compounds identified as potent CMV entry inhibitors. The research will evaluate the ability of NAPA compounds to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $430,604 to Imperial College London to conduct research on the role of placental macrophages in human cytomegalovirus (HCMV) infection at the maternal-fetal interface. The research aims to: 1) interrogate the temporal response of placental macrophages (Hofbauer cells) to HCMV infection, 2) elucidate the role of...
This federal Project Grant award of $887,405.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at harnessing cytomegalovirus (CMV) to improve the control of HIV-1 infection. The primary objectives are to: Optimize a panel of bi-specific chimeric antigen receptors (CARs) that recognize both CMV and HIV-1 antigens. This approach is intended to leverage the persistent...
The Project Grant award to Duke University in the amount of $213,284 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify factors that restrict human cytomegalovirus (HCMV) replication in trophoblasts, the primary placental cell type, and understand the impacts of HCMV infection on normal trophoblast function. The research aims to utilize trophoblast organoids as a model for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,812,152 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) on July 12, 2024. The award will fund a 5-center randomized clinical trial to compare preemptive therapy (PET) and antiviral prophylaxis (AP) for the prevention of cytomegalovirus (CMV) disease in 360 adult kidney transplant recipients (KTR) who are CMV...
This federal Project Grant award, valued at $134,269.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research conducted by Tufts University School of Medicine to structurally and antigenically characterize the glycoprotein B (gB) of the human cytomegalovirus (HCMV). The research aims to develop a stabilized, soluble prefusion form of gB (s-gBpre) as a reagent to...